AU Patent

AU2025279824A1 — Amorphous kinase inhibitor formulations and methods of use thereof

Assigned to Deciphera Pharmaceuticals LLC · Expires 2026-01-15 · 0y expired

What this patent protects

AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF Formula I Provided herein is an amorphous compound represented by Formula (I): and compositions thereof, which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFRα kinases, and …

USPTO Abstract

AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF Formula I Provided herein is an amorphous compound represented by Formula (I): and compositions thereof, which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFRα kinases, and oncogenic forms thereof. AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF

Drugs covered by this patent

Patent Metadata

Patent number: AU2025279824A1
Jurisdiction: AU
Classification: —
Expires: 2026-01-15
Drug substance claim: No
Drug product claim: No
Assignee: Deciphera Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.